Development of 1,3,4-Thiadiazole and Piperazine Fused Hybrid Quinazoline Derivatives as Dynamic Antimycobacterial Agents

References

• Global Tuberculosis Report 2020, World Health Organization. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf.
   Google Scholar
• H. Patel, A. Shirkhedkar, S. Bari, K. Patil, A. Arambhi, C. Pardeshi, A. Kulkarni, and S. Surana, “Quinazolino-Thiadiazoles as Antimicrobial Agents,” Bulletin of Faculty of Pharmacy, Cairo University 56, no. 1 (2018): 83–90.
   Google Scholar
• Z. Jiang, W. D. Hong, X. Cui, H. Gao, P. Wu, Y. Chen, D. Shen, Y. Yang, B. Zhang, M. J. Taylor, et al. “Synthesis and Structure-Activity Relationship of: N 4-benzylamine- N 2-Isopropyl-Quinazoline-2,4-Diamines Derivatives as Potential Antibacterial Agents,” RSC Advances 7, no. 82 (2017): 52227–37.
   Web of Science ®Google Scholar
• Y. Rojas-Aguirre, F. Hernández-Luis, C. Mendoza-Martínez, C. P. Sotomayor, L. F. Aguilar, F. Villena, I. Castillo, D. J. Hernández, and M. Suwalsky, “Effects of an Antimalarial Quinazoline Derivative on Human Erythrocytes and on Cell Membrane Molecular Models,” Biochimica et Biophysica Acta 1818, no. 3 (2012): 738–46.
   PubMed Web of Science ®Google Scholar
• L. A. Onambele, H. Riepl, R. Fischer, G. Pradel, A. Prokop, and M. N. Aminake, “Synthesis and Evaluation of the Antiplasmodial Activity of Tryptanthrin Derivatives,” International Journal for Parasitology. Drugs and Drug Resistance 5, no. 2 (2015): 48–57.
   PubMed Web of Science ®Google Scholar
• A. B. Patel, K. H. Chikhalia, and P. Kumari, “Access to Antimycobacterial and Anticancer Potential of Some Fused Quinazolines,” Research on Chemical Intermediates 41, no. 7 (2015): 4439–55.
   Web of Science ®Google Scholar
• S. Shagufta, and I. Ahmad, “An Insight into the Therapeutic Potential of Quinazoline Derivatives as Anticancer Agents,” MedChemComm 8, no. 5 (2017): 871–85.
   PubMed Web of Science ®Google Scholar
• A. M. Alafeefy, A. A. Kadi, O. A. Al-Deeb, K. E. H. El-Tahir, and N. A. Al-Jaber, “Synthesis, Analgesic and anti-Inflammatory Evaluation of Some Novel Quinazoline Derivatives,” European Journal of Medicinal Chemistry 45, no. 11 (2010): 4947–52.
   PubMed Web of Science ®Google Scholar
• E. Honkanen, A. Pippuri, P. Kairisalo, P. Nore, H. Karppanen, and I. Paakkari, “Synthesis and Antihypertensive Activity of Some New Quinazoline Derivatives,” Journal of Medicinal Chemistry 26, no. 10 (1983): 1433–8.
   PubMed Web of Science ®Google Scholar
• M. Saeedi, M. Mohammadi-Khanaposhtani, P. Pourrabia, N. Razzaghi, R. Ghadimi, S. Imanparast, M. A. Faramarzi, F. Bandarian, E. N. Esfahani, M. Safavi, et al. “Design and Synthesis of Novel Quinazolinone-1,2,3-Triazole Hybrids as New anti-Diabetic Agents: In Vitro α-Glucosidase Inhibition, Kinetic, and Docking Study,” Bioorganic Chemistry 83, (2019): 161–9.
   PubMed Web of Science ®Google Scholar
• L. Yurttaş, U. A. Mohsen, Y. Ozkan, S. Cobanoglu, S. Levent, and Z. A. Kaplancikli, “Synthesis and Biological Evaluation of Some Dibenzofuran-Piperazine Derivatives,” Journal of Enzyme Inhibition and Medicinal Chemistry 31, no. 6 (2016): 1177–83.
   PubMed Web of Science ®Google Scholar
• M. Patil, P. A. Noonikara, S. D. Joshi, S. A. Patil, S. A. Patil, and A. Bugarin, “Design, Synthesis, and Molecular Docking Study of New Piperazine Derivative as Potential Antimicrobial Agents,” Bioorganic Chemistry 92, (2019) : 103217.
   PubMed Web of Science ®Google Scholar
• A. B. Patel, K. H. Chikhalia, and P. Kumari, “Study of New β-Lactams-Substituted s-Triazine Derivatives as Potential Bioactive Agents,” Medicinal Chemistry Research 24, no. 2 (2015): 468–81.
   Web of Science ®Google Scholar
• V. Singh, A. Pacitto, S. Donini, D. M. Ferraris, S. Boros, E. Illyés, B. Szokol, M. Rizzi, T. L. Blundell, D. B. Ascher, et al. “Synthesis and Structure-Activity Relationship of 1-(5-Isoquinolinesulfonyl)Piperazine Analogues as Inhibitors of Mycobacterium Tuberculosis IMPDH,” European Journal of Medicinal Chemistry 174, (2019): 309–29.
   PubMed Web of Science ®Google Scholar
• Singireddi Srinivasarao, Adinarayana Nandikolla, Amaroju Suresh, Kevin Van Calster, Linda De Voogt, Davie Cappoen, Balaram Ghosh, Himanshu Aggarwal, Sankaranarayanan Murugesan, and Kondapalli Venkata Gowri Chandra Sekhar, “Seeking Potent anti-Tubercular Agents: Design and Synthesis of Substituted-: N-(6-(4-(Pyrazine-2-Carbonyl)Piperazine/Homopiperazine-1-yl)Pyridin-3-yl)Benzamide Derivatives as anti-Tubercular Agents,” RSC Advances 10, no. 21 (2020): 12272–88.
   PubMed Web of Science ®Google Scholar
• N. Sultana, M. S. Arayne, A. Naz, and M. A. Mesaik, “Identification of anti-Inflammatory and Other Biological Activities of 3-Carboxamide, 3-Carbohydrazide and Ester Derivatives of Gatifloxacin,” Chemistry Central Journal 7, no. 1 (2013): 6.
   PubMedGoogle Scholar
• A. Mendoza, S. Pérez-Silanes, M. Quiliano, A. Pabón, S. Galiano, G. González, G. Garavito, M. Zimic, A. Vaisberg, I. Aldana, et al. “Aryl Piperazine and Pyrrolidine as Antimalarial Agents. Synthesis and Investigation of Structure-Activity Relationships,” Experimental Parasitology 128, no. 2 (2011): 97–103.
   PubMed Web of Science ®Google Scholar
• E. Gurdal, E. Buclulgan, I. Durmaz, R. Cetin-Atalay, and Y. Yarim, “Synthesis and Anticancer Activity Evaluation of Some Benzothiazole-Piperazine Derivatives,” Anti-Cancer Agents in Medicinal Chemistry 15, no. 3 (2015): 382–9.
   PubMed Web of Science ®Google Scholar
• V. Raj, A. Rai, A. K. Singh, A. K. Keshari, and S. Saha, “Pharmacokinetics Studies of Single Orally Administered 1,3,4-Thiadiazoles: method Development and Validation,” International Journal of Pharmacokinetics 2, no. 4 (2017): 217–24.
   Google Scholar
• N. Siddiqui, P. Ahuja, S. Malik, and S. K. Arya, “Design of Benzothiazole-1,3,4-Thiadiazole Conjugates: Synthesis and Anticonvulsant Evaluation,” Archiv Der Pharmazie 346, no. 11 (2013): 819–31.
   PubMed Web of Science ®Google Scholar
• V. B. Jadhav, M. V. Kulkarni, V. P. Rasal, S. S. Biradar, and M. D. Vinay, “Synthesis and anti-Inflammatory Evaluation of Methylene Bridged Benzofuranyl Imidazo[2,1-b][1,3,4]Thiadiazoles,” European Journal of Medicinal Chemistry 43, no. 8 (2008): 1721–9.
   PubMed Web of Science ®Google Scholar
• S. S. Karki, K. Panjamurthy, S. Kumar, M. Nambiar, S. A. Ramareddy, K. K. Chiruvella, and S. C. Raghavan, “Synthesis and Biological Evaluation of Novel 2-Aralkyl-5-Substituted-6-(4'-Fluorophenyl)-Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives as Potent Anticancer Agents,” European Journal of Medicinal Chemistry 46, no. 6 (2011): 2109–16.
   PubMed Web of Science ®Google Scholar
• V. Raj, A. Rai, A. K. Singh, A. K. Keshari, P. Trivedi, B. Ghosh, U. Kumar, D. Kumar, and S. Saha, “Discovery of Novel 2-Amino-5-(Substituted)-1,3,4-Thiadiazole Derivatives: New Utilities for Colon Cancer Treatment,” Anti-Cancer Agents in Medicinal Chemistry 18, no. 5 (2018): 719–38.
   PubMed Web of Science ®Google Scholar
• V. Raj, M. H. Aboumanei, A. Rai, S. P. Verma, A. K. Singh, A. K. Keshari, and S. Saha, “Pharmacophore and 3d-Qsar Modeling of New 1,3,4-Thiadiazole Derivatives: Specificity to Colorectal Cancer,” Pharmaceutical Chemistry Journal 54, no. 1 (2020): 12–25.
   Web of Science ®Google Scholar
• V. Raj, A. S. Bhadauria, A. K. Singh, U. Kumar, A. Rai, A. K. Keshari, P. Kumar, D. Kumar, B. Maity, S. Nath, et al. “Novel 1,3,4-Thiadiazoles Inhibit Colorectal Cancer via Blockade of IL-6/COX-2 Mediated JAK2/STAT3 Signals as Evidenced through Data-Based Mathematical Modeling,” Cytokine 118, (2019) : 144–59.
   PubMed Web of Science ®Google Scholar
• V. Raj, A. Rai, and S. Saha, “Human Cancer Cell Line Based Approach of 1,3,4-Thiadiazole and Its Fused Ring: A Comprehensive Review,” Anti-Cancer Agents in Medicinal Chemistry 17, no. 4 (2017): 500–23.
   PubMed Web of Science ®Google Scholar
• S. G. Alegaon, and K. R. Alagawadi, “Synthesis, Characterization and Antimicrobial Activity Evaluation of New Imidazo [2,1-b][1,3,4]Thiadiazole Derivatives,” European Journal of Chemistry 2, no. 1 (2011): 94–9.
   Google Scholar
• G. Serban, O. Stanasel, E. Serban, and S. Bota, “2-Amino-1,3,4-Thiadiazole as a Potential Scaffold for Promising Antimicrobial Agents,” Drug Design, Development and Therapy 12, (2018) : 1545–66.
   PubMed Web of Science ®Google Scholar
• M. El-Naggar, H. A. Sallam, S. S. Shaban, S. S. Abdel-Wahab, A. E.-G E. Amr, M. E. Azab, E. S. Nossier, and M. A. Al-Omar, “Design, Synthesis, and Molecular Docking Study of Novel Heterocycles Incorporating 1,3,4-Thiadiazole Moiety as Potential Antimicrobial and Anticancer Agents,” Molecules 24, no. 6 (2019): 1066.
   PubMed Web of Science ®Google Scholar
• S. D. Joshi, K. Manish, and A. Badiger, “Synthesis and Evaluation of Antibacterial and Antitubercular Activities of Some Novel Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives,” Medicinal Chemistry Research 22, no. 2 (2013): 869–78.
   Web of Science ®Google Scholar
• A. K. Gadad, M. N. Noolvi, and R. V. Karpoormath, “Synthesis and anti-Tubercular Activity of a Series of 2-Sulfonamido/Trifluoromethyl-6-Substituted Imidazo[2,1-b]-1,3,4-Thiadiazole Derivatives,” Bioorganic & Medicinal Chemistry 12, no. 21 (2004): 5651–9.
   PubMed Web of Science ®Google Scholar
• E. E. Oruç, S. Rollas, F. Kandemirli, N. Shvets, and A. S. Dimoglo, “1,3,4-thiadiazole Derivatives. Synthesis, Structure Elucidation, and Structure-Antituberculosis Activity Relationship Investigation,” Journal of Medicinal Chemistry 47, no. 27 (2004): 6760–7.
   PubMed Web of Science ®Google Scholar
• H. M. Patel, M. N. Noolvi, N. S. Sethi, A. K. Gadad, and S. S. Cameotra, “Synthesis and Antitubercular Evaluation of Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives,” Arabian Journal of Chemistry 10, no. 1 (2017): S996–S1002.
   Google Scholar
• H.-J. Wang, C.-X. Wei, X.-Q. Deng, F.-L. Li, and Z.-S. Quan, “Synthesis and Evaluation on Anticonvulsant and Antidepressant Activities of 5-Alkoxy-tetrazolo[1,5-a]quinazolines,” Archiv Der Pharmazie 342, no. 11 (2009): 671–5.
   PubMed Web of Science ®Google Scholar
• A. B. Patel, K. H. Chikhalia, and P. Kumari, “Facile Synthesis of Benzonitrile/Nicotinonitrile Based s-Triazines as New Potential Antimycobacterial Agents,” European Journal of Medicinal Chemistry 79, (2014) : 57–65.
   PubMed Web of Science ®Google Scholar
• R. V. Patel, J. K. Patel, P. Kumari, and K. H. Chikhalia, “Synthesis of Novel Quinolone and Coumarin Based 1,3,4-Thiadiazolyl and 1,3,4-Oxadiazolyl N-Mannich Bases as Potential Antimicrobials,” Letters in Organic Chemistry 9, no. 7 (2012): 478–86.
   Web of Science ®Google Scholar
• P. Anargyros, D. S. J. Astill, and I. S. L. Lim, “Comparison of Improved BACTEC and Lowenstein-Jensen Media for Culture of Mycobacteria from Clinical Specimens,” Journal of Clinical Microbiology 28, no. 6 (1990): 1288–91.
   PubMed Web of Science ®Google Scholar
• A. L. Leber, Clinical Microbiology Procedures Handbook, ASM Press, Washington, DC, 2016.
   Google Scholar
• M.-X. Song, X.-Q. Deng, Y.-R. Li, C.-J. Zheng, L. Hong, and H.-R. Piao, “Synthesis and Biological Evaluation of (E)-1-(Substituted)-3-Phenylprop-2-en-1-Ones Bearing Rhodanines as Potent anti-Microbial Agents,” Journal of Enzyme Inhibition and Medicinal Chemistry 29, no. 5 (2014): 647–53.
   PubMed Web of Science ®Google Scholar